PRN: Global ENT Disorder Treatment Market Report 2017 -Research and Markets

31/mag/2017 15:40:11 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global ENT Disorder Treatment Market Report 2017 -Research and Markets


DUBLIN, May 31, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global ENT Disorder Treatment Market 2017-2021" report to their offering.

Research and Markets Logo

The global ENT disorder treatment market to grow at a CAGR of 2.17% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global ENT disorder treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales from both branded and generic drugs. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in market is increase in research on allergic disorders. Allergic diseases such as rhinitis, if not managed properly, have chances of developing into organizations around the world are working to have a better understanding of the pathogenesis of allergic diseases.

According to the report, one driver in market is deteriorating environmental conditions. Deteriorating environmental conditions is one of the major reasons for the rising prevalence of ENT disorders such as rhinitis. For instance, perennial allergic rhinitis can prevail around the year and is often the result of sensitivity to mold on wallpaper, pet hair, carpeting, houseplants, and upholstery.

Further, the report states that one challenges in market is growing cases of anti-bacterial resistance. Antimicrobial resistance is one of the major public health challenges faced globally, and has been accelerated by the overuse of antibiotics across the globe. Overprescribing antibiotics is a common problem in primary care, where most of the infections are caused by viruses.

Key vendors

  • ALK
  • GSK
  • Novartis
  • Sanofi

Other prominent vendors

  • Allergan
  • AstraZeneca
  • Dr. Reddy's Laboratories
  • Lupin
  • Merck
  • Mylan
  • Otonomy
  • Pfizer
  • Sun Pharma
  • Teva Pharmaceuticals

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Market landscape

Part 07: Pipeline landscape

Part 08: Market segmentation by disease

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

Part 15: Appendix

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl